• Daniel B Herrick, Wendy C Ziai, Carol B Thompson, Karen Lane, Nichol A McBee, and Daniel F Hanley.
• Department of Neurology, Johns Hopkins University, School of Medicine, BA, 1550 Orleans Street, CRB-II 3M50, Baltimore, MD 21231, USA. daniel.herrick@tufts.edu
• Stroke. 2011 Dec 1;42(12):3631-3.

Background And PurposeThis is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).MethodsLaboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.ResultsPlasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant impact on any systemic coagulation parameters in either treatment group.ConclusionsIntraventricular recombinant tissue-type plasminogen activator is unlikely to impact systemic coagulation or to compound the effects of systemic anticoagulation for deep venous thrombosis prophylaxis.Clinical Trial RegistrationURL: http://clinicaltrials.gov. Unique identifier: NCT00650858.

25 keywords...

hide…